Linked Life Data

7984694

Source:http://linkedlifedata.com/resource/pubmed/id/7984694

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1995-1-4
pubmed:abstractText
Lisuride--a compound with mainly dopamine d2-agonistic, but also dl-antagonistic and serotonergic properties was choosen in 1.0 mg daily dose as an anticraving drug for keeping alcoholics abstinent who had been included in a randomized double-blind placebo-controlled trial for 6 months. Preliminary results indicate that in the first 55 recruited patients the overall abstinence-rate dropped from 85% after 3 months to 47% after 6 months. Predictors of relapse were early onset of alcohol-related problems, a high number of preceding detoxification and rehabilitation treatments, intermittant drinking habits, less feeling of guilt and low harm avoidance in the TPQ by Cloninger. More details will be given after completing the study when the code is lifted.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0176-3679
pubmed:author
pubmed:issnType
Print
pubmed:volume
27 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
21-3
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Relapse prevention in alcoholics with an anticraving drug treatment: first results of the Berlin Study.
pubmed:affiliation
Department of Psychiatry, Free University of Berlin, Germany.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial